Why the study?
Do angiotensin II receptor antagonists offer specific pharmacological or clinical advantages over ACE inhibitors in the treatment of cardiovascular disease?
Do angiotensin II receptor antagonists offer specific pharmacological or clinical advantages over ACE inhibitors in the treatment of cardiovascular disease?
Answers are grounded in this paper and cite their sources.
This review explores the potential pharmacological and clinical differences between angiotensin II receptor antagonists and ACE inhibitors.
Over the past several years, angiotensin I converting enzyme (ACE) inhibitors, compounds that block the formation of angiotensin II (ANG II), have become widely used in the treatment of cardiovascular disease. Recently, a new class of orally active, non-peptide inhibitors of the renin-angiotensin system, the ANG II receptor antagonists have also become available. Since both classes of compounds block the renin-angiotensin system, although at different sites, it remains to be determined whether blockade of ANG II receptors will have any specific advantage over inhibition of ACE. The following review assesses the actions of ANG II antagonists and suggests ways in which blockade of ANG II receptors may differ both pharmacologically and clinically from inhibition of ACE.
No takes yet. Share an insight, caveat, or question.
Levens et al. (1992) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: